Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716380 | 0.79 | MEN1 (0.41) | KMT2AMEN1CTSK | |
| SCHEMBL23970178 | 0.79 | MEN1 (0.41) | KMT2AMEN1CTSK | |
| SCHEMBL16203420 | 0.79 | MEN1 (0.41) | KMT2AMEN1CTSK | |
| SCHEMBL756416 | 0.79 | GRN (0.36) | KMT2AMEN1CTSKCNR2 | |
| SCHEMBL5850026 | 0.79 | CYP2D6 (0.40) | CTSKCNR2 | |
| SCHEMBL3599965 | 0.79 | CYP2D6 (0.40) | CTSKCNR2 | |
| SCHEMBL3599961 | 0.79 | CYP2D6 (0.40) | CTSKCNR2 | |
| SCHEMBL25589751 | 0.78 | MEN1 (0.40) | KMT2AMEN1CTSK | |
| SCHEMBL13996915 | 0.78 | MEN1 (0.40) | KMT2AMEN1CTSK | |
| SCHEMBL25590340 | 0.77 | MEN1 (0.39) | KMT2AMEN1CTSKCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887007-A2 | Novel compounds | AstraZeneca AB (SE) | 2008-02-13 | — | — | EP | claimed |
| EP-1625126-B1 | IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | claimed |
| US-20060287355-A1 | Imidazo and thiazolopyridines as jak3 kinase inhibitors | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | claimed |
| EP-1887007-A2 | Novel compounds | AstraZeneca AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1625126-B1 | IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| US-20060287355-A1 | Imidazo and thiazolopyridines as jak3 kinase inhibitors | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287355-A1 | Imidazo and thiazolopyridines as jak3 kinase inhibitors | JAK3, JAK2, JAK1 | KMT2A 1339/4885MEN1 3986/4885CTSK 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.